May 20 (Reuters) - Regeneron Pharmaceuticals Inc said it settled all pending litigation with Roche Holding AG's unit Genentech on the company's eye drug, Eylea, and cancer drug, Zaltrap.
AstraZeneca plans to advance its three cancer drug candidates into Phase III trials. -More- …
Bristol-Myers Squibb has emerged, at least temporarily, as the leader in a race to develop the first new PD-1 drug to fight cancer.
The FDA approved Bayer and Algeta's Xofigo injection, or radium-223 dichloride, to treat patients with castration-resistant p -More- …
